Autosomal Dominant Polycystic Kidney Disease (ADPKD) Clinical Trial
Official title:
A Multi-center, Longitudinal, Observational Study of Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) to Establish the Rate, Characteristics, and Determinants of Disease Progression
To collect characteristics of patients with ADPKD across a broad population, over time to better understand disease progression (signs, symptoms and outcomes). Association with total kidney volume changes and other measures of disease progression will be determined in order to identify a population at increased risk for disease progression. The economic and quality life impact of ADPKD will be assessed. Subjects who terminated participation early from clinical trials with tolvaptan may also be followed.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02964273 -
Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)
|
Phase 3 | |
| Terminated |
NCT01223755 -
Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency
|
Phase 2/Phase 3 | |
| Completed |
NCT01280721 -
A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]
|
Phase 3 | |
| Completed |
NCT01214421 -
Tolvaptan Extension Study in Participants With ADPKD
|
Phase 3 | |
| Completed |
NCT02225860 -
Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT01616927 -
Study of Lanreotide to Treat Polycystic Kidney Disease
|
Phase 3 | |
| Completed |
NCT00346918 -
Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 3 | |
| Completed |
NCT03949894 -
Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease
|
Phase 4 | |
| Recruiting |
NCT02925221 -
Canadian Medical Assessment of JINARC™ Outcomes Registry
|
||
| Completed |
NCT04689074 -
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases
|
||
| Terminated |
NCT02616055 -
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
|
Phase 2 | |
| Recruiting |
NCT06289998 -
Study of Tamibarotene in Patients With ADPKD
|
Phase 2 | |
| Completed |
NCT02112136 -
Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD
|
N/A | |
| Recruiting |
NCT02115659 -
Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 3 | |
| Completed |
NCT00309283 -
Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study
|
Phase 3 | |
| Recruiting |
NCT06345755 -
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of VX-407 in Healthy Participants
|
Phase 1 |